Journal
JOURNAL OF ORTHOPAEDIC RESEARCH
Volume 31, Issue 3, Pages 401-406Publisher
WILEY-BLACKWELL
DOI: 10.1002/jor.22243
Keywords
INFUSE bone graft; recombinant human bone morphogenic protein-2 (rhBMP2); absorbable collagen sponge (ACS); delivery vehicle; hydrogel
Categories
Funding
- Howard Hughes Medical Institute
- NIH [5R01DE016523, 5R21AR057904]
Ask authors/readers for more resources
Medtronic's INFUSE Bone Graft provides surgeons with a potent tool for stimulating bone formation. Current delivery vehicles that rely on Absorbable Collagen Sponges (ACS) require excessive quantities of the active ingredient in INFUSE, recombinant human Bone Morphogenic Protein-2 (rhBMP2), to achieve physiologically relevant concentrations of the growth factor, driving up the cost of the product and increasing the likelihood of undesirable side effects in neighboring tissues. We demonstrate that a simple light-mediated, thiol-ene chemistry can be used to create an effective polymer delivery vehicle for rhBMP2, eliminating the use of xenographic materials and reducing the dose of rhBMP2 required to achieve therapeutic effects. Comprised entirely of synthetic components, this system entraps rhBMP2 within a biocompatible hydrogel scaffold that is degraded by naturally occurring remodeling enzymes, clearing the way for new tissue formation. When tested side-by-side with ACS in a critical-sized bone defect model in rats, this polymeric delivery system significantly increased bone formation over ACS controls. (C) 2012 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 31: 401406, 2013
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available